FT-03

FT-03 is an investigational small molecule drug candidate currently in the preclinical stage of development by Fekra Therapeutics. It is being developed for the treatment of non-solid tumors, a broad category that encompasses various hematological malignancies such as leukemias, lymphomas, and myelomas. Fekra Therapeutics is a clinical-stage biotechnology company focused on the discovery and development of next-generation small molecule targeted therapies, particularly those utilizing a covalent inhibition platform. While the company has disclosed specific molecular targets for its lead programs—such as BMX for FT-01 and KRAS G12C for FT-02—the specific target and mechanism of action for FT-03 have not yet been publicly disclosed. The program represents part of Fekra's oncology pipeline aimed at addressing unmet needs in blood-based cancers through precision medicine.

Other names

Fekra-03Fekra03Fekra 03